AXA SA Share Price Other OTC
Stocks
AXAHY
US0545361075
Life & Health Insurance
OTC Markets Traded| Market Cap | 8.84TCr 10TCr 8.34TCr 7.56TCr 14TCr 9,75000Cr 14TCr 1LCr 38TCr 4,95900Cr 38TCr 37TCr 15,74600Cr | P/E 2026 * |
10.6x | P/E 2027 * | 9.63x |
|---|---|---|---|---|---|
| Enterprise Value | 10TCr 12TCr 9.81TCr 8.89TCr 17TCr 11,47100Cr 17TCr 1,17100Cr 45TCr 5,83400Cr 45TCr 44TCr 18,52600Cr | EV / Sales 2026 * |
0.91x | EV / Sales 2027 * | 0.87x |
| Free-Float |
77.71% | Yield 2026 * |
5.75% | Yield 2027 * | 6.21% |
Last Transcript: AXA SA
| 1 day | +0.96% |
| Manager | Title | Age | Since |
|---|---|---|---|
Thomas Buberl
CEO | Chief Executive Officer | 53 | 01/09/2016 |
| Director of Finance/CFO | - | 01/07/2021 | |
Guillaume Borie
CTO | Chief Tech/Sci/R&D Officer | 40 | 01/12/2025 |
| Director | Title | Age | Since |
|---|---|---|---|
Thomas Buberl
BRD | Director/Board Member | 53 | 01/09/2016 |
| Director/Board Member | 68 | 27/04/2016 | |
Helen Browne
BRD | Director/Board Member | 63 | 30/06/2020 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +0.96% | +2.00% | - | - | 10TCr | ||
| -0.18% | -6.03% | -5.11% | +10.57% | 14TCr | ||
| +1.11% | -2.17% | +8.60% | +52.80% | 10TCr | ||
| +0.53% | -2.65% | -0.46% | +12.53% | 9.86TCr | ||
| +0.29% | +0.76% | +36.88% | +131.91% | 7.91TCr | ||
| +0.46% | -1.27% | +37.20% | +137.21% | 7.21TCr | ||
| +0.63% | +0.13% | +20.95% | +53.24% | 6.17TCr | ||
| +0.10% | +0.15% | +69.06% | +132.23% | 5.98TCr | ||
| +1.50% | -0.17% | +7.22% | +53.17% | 5.78TCr | ||
| +1.81% | -2.17% | +71.76% | +140.64% | 5.13TCr | ||
| Average | +0.72% | -1.38% | +27.34% | +80.48% | 8TCr | |
| Weighted average by Cap. | +0.63% | -1.58% | +21.15% | +69.22% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 11TCr 13TCr 11TCr 9.74TCr 18TCr 12,56100Cr 18TCr 1,28300Cr 49TCr 6,38800Cr 49TCr 48TCr 20,28600Cr | 12TCr 14TCr 11TCr 10TCr 19TCr 13,15700Cr 19TCr 1,34400Cr 52TCr 6,69200Cr 52TCr 51TCr 21,25000Cr |
| Net income | 842.06Cr 972.65Cr 794.66Cr 720.28Cr 1.35TCr 93TCr 1.36TCr 9.49TCr 3.66TCr 47TCr 3.65TCr 3.57TCr 1,50100Cr | 900.04Cr 1.04TCr 849.38Cr 769.88Cr 1.44TCr 99TCr 1.46TCr 10TCr 3.91TCr 51TCr 3.9TCr 3.82TCr 1,60400Cr |
| Net Debt | 1.56TCr 1.8TCr 1.47TCr 1.33TCr 2.5TCr 1,72100Cr 2.52TCr 18TCr 6.77TCr 88TCr 6.76TCr 6.62TCr 2,78000Cr | 1.56TCr 1.8TCr 1.47TCr 1.33TCr 2.5TCr 1,72100Cr 2.52TCr 18TCr 6.77TCr 88TCr 6.76TCr 6.62TCr 2,78000Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.

















